MX2016008466A - 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. - Google Patents
99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana.Info
- Publication number
- MX2016008466A MX2016008466A MX2016008466A MX2016008466A MX2016008466A MX 2016008466 A MX2016008466 A MX 2016008466A MX 2016008466 A MX2016008466 A MX 2016008466A MX 2016008466 A MX2016008466 A MX 2016008466A MX 2016008466 A MX2016008466 A MX 2016008466A
- Authority
- MX
- Mexico
- Prior art keywords
- radiopharmaceutical
- hynic
- ipsma
- edda
- 99mtc
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract 5
- 239000012217 radiopharmaceutical Substances 0.000 title abstract 5
- 229940121896 radiopharmaceutical Drugs 0.000 title abstract 5
- 230000002799 radiopharmaceutical effect Effects 0.000 title abstract 5
- 230000002018 overexpression Effects 0.000 title abstract 2
- KOUZWQLNUJWNIA-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=NC=CC=C1C(N)=O KOUZWQLNUJWNIA-UHFFFAOYSA-N 0.000 abstract 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 2
- 230000035945 sensitivity Effects 0.000 abstract 2
- 238000002603 single-photon emission computed tomography Methods 0.000 abstract 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 125000003636 chemical group Chemical group 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención se refiere un nuevo radiofármaco inhibidor del antígeno prostático específico de membrana (iPSMA) que contiene hidrazinonicotinamida (HYNIC) como un grupo químico crítico en el incremento de la lipofilia de la molécula para el acoplamiento a los sitios hidrófobos del PSMA, aunado al uso convencional del HYNIC como un agente quelante para el radiometal 99mTc, donde el ácido etilendiaminodiacético (EDDA) es usado para completar la esfera de coordinación del radiometal. El nuevo radiofármaco de 99mTc-EDDA/HYNIC-iPSMA detecta, con alta afinidad y sensibilidad in vivo, a la proteína PSMA sobre-expresada en células de cáncer de próstata mediante técnicas de imagen molecular SPECT en medicina nuclear. El objeto de esta invención es proporcionar un nuevo radiofármaco específico (radiofármaco de blancos moleculares) de SPECT con alta sensibilidad para la detección de tumores con sobre-expresión de PSMA.
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016008466A MX2016008466A (es) | 2016-06-24 | 2016-06-24 | 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. |
| PCT/MX2017/000068 WO2017222362A1 (es) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma como un radiofármaco para la detección de la sobre-expresión del antigeno prostático de membrana |
| PL17815772T PL3486249T3 (pl) | 2016-06-24 | 2017-06-21 | 99mTc-EDDA/HYNIC-IPSMA JAKO RADIOFARMACEUTYK DO WYKRYWANIA NADEKSPRESJI ANTYGENU BŁONOWEGO SWOISTEGO DLA PROSTATY |
| CN201780049494.4A CN109641924B (zh) | 2016-06-24 | 2017-06-21 | 作为检测前列腺特异性膜抗原的过表达的放射性药物的99mtc-edda/hynic-ipsma |
| ES17815772T ES2906332T3 (es) | 2016-06-24 | 2017-06-21 | 99MTc-EDDA/HYNIC-iPSMA como un radiofármaco para detectar la sobreexpresión de antígeno prostático específico de membrana |
| DK17815772.3T DK3486249T3 (da) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma som et radiofarmaceutisk middel til detektering af overekspressionen af prostata-specifikt membranantigen |
| CA3059545A CA3059545C (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| BR112018076593-7A BR112018076593B1 (pt) | 2016-06-24 | 2017-06-21 | Composto para radiomarcação, composto radiofarmacêutica, e composição radiofarmacêutica |
| HUE17815772A HUE057891T2 (hu) | 2016-06-24 | 2017-06-21 | 99MTC-EDDA/HYNIC-IPSMA mint radiofarmakon a prosztataspecifikus membrán antigén túlzott expressziójának kimutatására |
| PT178157723T PT3486249T (pt) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma como um radiofármaco para a deteção da hiperexpressão do antigénio da membrana específico da próstata |
| US16/310,744 US10918745B2 (en) | 2016-06-24 | 2017-06-21 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate specific membrane antigen |
| EP17815772.3A EP3486249B1 (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| MA045687A MA45687A (fr) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma à utiliser en tant que radiopharmaceutique pour détecter la surexpression de l'antigène membranaire spécifique de la prostate |
| EA201892668A EA201892668A1 (ru) | 2016-06-24 | 2017-06-21 | Tc-EDDA/HYNIC-iPSMA В КАЧЕСТВЕ РАДИОФАРМАЦЕВТИЧЕСКОГО ПРЕПАРАТА ДЛЯ ОБНАРУЖЕНИЯ СВЕРХЭКСПРЕССИИ ПРОСТАТСПЕЦИФИЧЕСКОГО МЕМБРАННОГО АНТИГЕНА |
| EP21205156.9A EP4083049A3 (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| ZA2018/07828A ZA201807828B (en) | 2016-06-24 | 2018-11-20 | 99m tc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
| US17/135,424 US11547767B2 (en) | 2016-06-24 | 2020-12-28 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2016008466A MX2016008466A (es) | 2016-06-24 | 2016-06-24 | 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008466A true MX2016008466A (es) | 2017-12-25 |
Family
ID=60783979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008466A MX2016008466A (es) | 2016-06-24 | 2016-06-24 | 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10918745B2 (es) |
| EP (2) | EP3486249B1 (es) |
| CN (1) | CN109641924B (es) |
| BR (1) | BR112018076593B1 (es) |
| CA (1) | CA3059545C (es) |
| DK (1) | DK3486249T3 (es) |
| EA (1) | EA201892668A1 (es) |
| ES (1) | ES2906332T3 (es) |
| HU (1) | HUE057891T2 (es) |
| MA (1) | MA45687A (es) |
| MX (1) | MX2016008466A (es) |
| PL (1) | PL3486249T3 (es) |
| PT (1) | PT3486249T (es) |
| WO (1) | WO2017222362A1 (es) |
| ZA (1) | ZA201807828B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380340B (es) * | 2018-03-14 | 2025-03-11 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
| PL239934B1 (pl) * | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
| CN111233758B (zh) * | 2020-03-02 | 2021-04-23 | 北京大学第一医院 | 一种psma抑制剂及其应用和靶向psma的核素成像试剂 |
| CN111253465A (zh) * | 2020-03-03 | 2020-06-09 | 复旦大学附属肿瘤医院 | 一种psma结合剂及其用途 |
| CA3176404A1 (en) * | 2020-04-24 | 2021-10-28 | Ebrahim S. Delpassand | Composition, kit and method for diagnosis and treatment of prostate cancer |
| MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
| CN117500772A (zh) | 2021-05-31 | 2024-02-02 | 泰利克斯制药(创新)私人有限公司 | 改进的前列腺特异性膜抗原靶向放射性药物及其用途 |
| CN115745903B (zh) * | 2021-09-03 | 2024-07-23 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN114569744A (zh) * | 2022-03-08 | 2022-06-03 | 安徽淮仁堂药业股份有限公司 | 一种锝前列腺标特异性膜抗原显像剂试剂盒及其制备方法和应用 |
| CN115260155B (zh) * | 2022-08-08 | 2023-11-10 | 北京师范大学 | 一种含三唑环和肼基尼古酰胺基的谷氨酸-脲衍生物及其应用 |
| CN117434270B (zh) * | 2023-09-11 | 2024-05-07 | 江苏省人民医院（南京医科大学第一附属医院） | 一种可携带放射性信号的蛋白质支架及其抗体检测中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104774175B (zh) | 2007-06-26 | 2019-04-16 | 约翰·霍普金斯大学 | 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途 |
| MX336322B (es) | 2010-04-08 | 2016-01-12 | Inst Nac De Investigaciones Nucleares | 99mtc-edda/hynic-ggc-aunp-manosa como un nuevo radiofarmaco para la deteccion del ganglio centinela en cancer de mama. |
| CN102949735B (zh) * | 2011-08-30 | 2015-06-10 | 北京大基康明医疗设备有限公司 | 放射性药物的制备方法及系统 |
| PT2836241T (pt) * | 2012-04-10 | 2019-05-30 | Lantheus Medical Imaging Inc | Métodos de síntese de radiofármacos |
| WO2016062370A1 (en) * | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
-
2016
- 2016-06-24 MX MX2016008466A patent/MX2016008466A/es unknown
-
2017
- 2017-06-21 PT PT178157723T patent/PT3486249T/pt unknown
- 2017-06-21 US US16/310,744 patent/US10918745B2/en active Active
- 2017-06-21 HU HUE17815772A patent/HUE057891T2/hu unknown
- 2017-06-21 WO PCT/MX2017/000068 patent/WO2017222362A1/es unknown
- 2017-06-21 MA MA045687A patent/MA45687A/fr unknown
- 2017-06-21 EP EP17815772.3A patent/EP3486249B1/en active Active
- 2017-06-21 CN CN201780049494.4A patent/CN109641924B/zh active Active
- 2017-06-21 PL PL17815772T patent/PL3486249T3/pl unknown
- 2017-06-21 ES ES17815772T patent/ES2906332T3/es active Active
- 2017-06-21 CA CA3059545A patent/CA3059545C/en active Active
- 2017-06-21 DK DK17815772.3T patent/DK3486249T3/da active
- 2017-06-21 BR BR112018076593-7A patent/BR112018076593B1/pt active IP Right Grant
- 2017-06-21 EP EP21205156.9A patent/EP4083049A3/en active Pending
- 2017-06-21 EA EA201892668A patent/EA201892668A1/ru unknown
-
2018
- 2018-11-20 ZA ZA2018/07828A patent/ZA201807828B/en unknown
-
2020
- 2020-12-28 US US17/135,424 patent/US11547767B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3486249T3 (da) | 2022-02-07 |
| EP3486249A1 (en) | 2019-05-22 |
| US11547767B2 (en) | 2023-01-10 |
| BR112018076593B1 (pt) | 2022-05-24 |
| ES2906332T3 (es) | 2022-04-18 |
| HUE057891T2 (hu) | 2022-06-28 |
| WO2017222362A1 (es) | 2017-12-28 |
| CN109641924B (zh) | 2022-02-25 |
| CN109641924A (zh) | 2019-04-16 |
| EP4083049A2 (en) | 2022-11-02 |
| EP3486249B1 (en) | 2021-11-10 |
| EP3486249A4 (en) | 2020-03-11 |
| PT3486249T (pt) | 2022-02-02 |
| PL3486249T3 (pl) | 2022-05-23 |
| EP4083049A3 (en) | 2022-12-21 |
| CA3059545C (en) | 2021-07-27 |
| CA3059545A1 (en) | 2017-12-28 |
| EA201892668A1 (ru) | 2019-10-31 |
| US20210187132A1 (en) | 2021-06-24 |
| US20190343970A1 (en) | 2019-11-14 |
| BR112018076593A2 (pt) | 2019-04-16 |
| ZA201807828B (en) | 2021-03-31 |
| US10918745B2 (en) | 2021-02-16 |
| MA45687A (fr) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008466A (es) | 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. | |
| Mitran et al. | Bispecific GRPR-antagonistic anti-PSMA/GRPR heterodimer for PET and SPECT diagnostic imaging of prostate cancer | |
| Pillai et al. | Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer | |
| Eder et al. | Novel preclinical and radiopharmaceutical aspects of [68Ga] Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer | |
| WO2015073746A3 (en) | 18f labeling of proteins using sortases | |
| MX2015000684A (es) | Metodo para detectar cancer. | |
| Rinne et al. | PET and SPECT imaging of the EGFR family (RTK class I) in oncology | |
| MX357292B (es) | Método para detectar cáncer. | |
| Dahlsson Leitao et al. | Molecular design of HER3-targeting affibody molecules: influence of chelator and presence of HEHEHE-tag on biodistribution of 68Ga-labeled tracers | |
| Oroujeni et al. | Preclinical evaluation of [68Ga] Ga-DFO-ZEGFR: 2377: A promising affibody-based probe for noninvasive PET imaging of EGFR expression in tumors | |
| Guo et al. | Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide | |
| Abouzayed et al. | Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer | |
| Da Pieve et al. | New fully automated preparation of high apparent molar activity 68Ga-FAPI-46 on a Trasis AiO platform | |
| Rinne et al. | 66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga] Ga-NOTA-PEG2-RM26 | |
| Deyev et al. | Influence of the position and composition of radiometals and radioiodine labels on imaging of Epcam expression in prostate cancer model using the DARPin Ec1 | |
| Yordanova et al. | Advances in molecular imaging and radionuclide therapy of neuroendocrine tumors | |
| Lundmark et al. | Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation | |
| Vahidfar et al. | Diagnostic value of radiolabelled somatostatin analogues for neuroendocrine tumour diagnosis: the benefits and drawbacks of [64Cu] Cu-DOTA-TOC | |
| Rinne et al. | Benefit of later-time-point PET imaging of HER3 expression using optimized radiocobalt-labeled affibody molecules | |
| Rinne et al. | Influence of residualizing properties of the radiolabel on radionuclide molecular imaging of HER3 using affibody molecules | |
| Obeid et al. | GRPR-antagonists carrying DOTAGA-chelator via positively charged linkers: Perspectives for prostate cancer theranostics | |
| Larkina et al. | Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer | |
| Oroujeni et al. | Evaluation of tumor-targeting properties of an antagonistic bombesin analogue RM26 conjugated with a non-residualizing radioiodine label comparison with a radiometal-labelled counterpart | |
| Zhang et al. | Imageological/structural study regarding the improved pharmacokinetics by 68Ga-Labeled PEGylated PSMA multimer in prostate cancer | |
| ZA202401715B (en) | Radiopharmaceuticals based on ((r)-1-((6-hydrazinylnicotinoyl)-dalanyl) pyrrolidin-2-yl)boronic acid (hynic-ifap) for detecting the overexpression of fibroblast activation protein |